BIG helps its partners reach growth milestones at an accelerated rate.
As a BIG partner, you have access to state-of-the-art facilities and specialists in research, clinical practice, data management, analytics and omics. Our partners benefit from the resources available at UB, including tailored business support services and access to additional funding programs.
BIG partners with companies to provide them access to expertise, research capabilities and supercomputing resources. This boosts the creation of new approaches to personalized medicine, diagnostics and technologies created in Western New York.
ZeptoMetrix® is the industry leader for innovative solutions to challenges in the evolving Infectious Disease Diagnostics market. From assay conception to launch, scientific and operational teams provide customers with comprehensive, performance-oriented and cost-effective products and services that positively impact the field of clinical diagnostics and its contribution to global healthcare.
A partnership with BIG will help the firm expand in this market. Through BIG, ZeptoMetrix has access to a high-tech instrumentation system in UB’s Center of Excellence in Bioinformatics and Life Sciences, where the company leases lab space. ZeptoMetrix expects to create new jobs in the region over five years in addition to hiring UB students as interns and engaging in collaborative research with university scientists on topics that could include oncology diagnostics.
Circuit Clinical personalizes medicine by bringing studies to the physicians that patients know and trust. The company streamlines the process while removing cost for physicians in order to bring new medical solutions to patients.
As part of its engagement with BIG, Circuit Clinical will expand its technology platform and bring software development jobs to Buffalo.
Garwood Medical is an advanced medical device company whose products will positively enhance clinical outcomes related to infection. Through advanced technology and novel designs, Garwood Medical is committed to disrupt the wound care and perio-prosthetic market by advancing infection control through innovation.
A strategic partnership with BIG provides the company with a state of the art research and development site and a robust university engineering team. This public-private partnership will drive Garwood’s and UB’s technologies through development, by performing all aspects of research, device modeling, rational product design and prototyping, focusing on verifications, validations and characterizations of the applications and imbedded technologies.
Tactiva is a development stage immuno-oncology company with a unique approach to adoptive T-cell therapy. Tactiva's dual enhanced adoptive cell therapy (DEACT™) platform, consists of engineered CD4/CD8 cells which generate a durable supply of CD4 cells with direct anti-tumor activity as well as sustained helper function to CD8 T cell derived TCR-transduced effector T cells. Tactiva Therapeutics is working to develop the next generation of cancer immunotherapies by utilizing a new approach to cell therapy. This type of personalized cancer treatment enhances the patient's immune system ability to tackle the disease.
Tactiva Therapeutics has been a partner to the University at Buffalo’s since January 2017 when it colocated at the New York State Center of Excellence in Bioinformatics and Life Sciences on the Buffalo Niagara Medical Campus.
Through the partnership with the University at Buffalo, Tactiva Therapeutics has received funding support from the UB Center for Advanced Technology in Big Data and Health Sciences that enabled a collaboration with UB’s Genomics and Bioinformatics Core, infrastructure that was funded by BIG in support of Tactiva’s discovery efforts.
The partnership with BIG provides Tactiva Therapeutics with access to equipment for their preclinical development of Tactiva’s DEACTTM platform.
The prevalence of autoimmune diseases is as high as 20%, affecting over 50 million people in the United States. They are associated with significant morbidity and mortality. Early diagnosis of autoimmune diseases is crucial for optimal management.
Aesku NY, Inc. is established with a focus on the development, manufacturing and distribution of in vitro diagnostic reagents and test methods mostly for autoimmune diseases that may be used in combination with Aesku’s proprietary HELIOS system. This system is a fully automated end-to-end for processing of specimens for immuno-fluorescence staining and for interpretation of the results using an algorithm pattern library to give the most accurate diagnosis with the most favorable outcomes for a patient.
Through accessing specialized equipment funded by BIG, Aesku will be able to further their research and manufacturing capabilities to meet the growing market demands of products on the HELIOS system. Aesku is also collaborating with several researchers at the University at Buffalo for the identification and development of novel bio-markers to be incorporated into their product line.
KSL is a Buffalo-based company advancing translational medicine and improving the delivery of personalized medicine through the development of novel genomic- and proteomic-based diagnostics for cancers and orphan diseases. The company has a robust pipeline of proprietary products and services at various stages of development and regulatory clearance in the United States and the rest of the world.
KSL will have access to biological materials from BIG’s biorepository and is working with UB equipment to develop and validate its genomics-based diagnostics products. The company has an internship program through UB and recruits UB graduates.
Located within UB’s New York State Center of Excellence in Bioinformatics and Life Sciences, AHRM Inc. is a global contract research organization with a focus on health care informatics, economics and outcomes research. Through advanced analytics, AHRM provides research support services for biotech companies, including those in the pharmaceutical and medical devices industries, as well as clinics and non-profits.
The partnership between BIG and AHRM will facilitate access to the supercomputing cluster at UB’s Center for Computational Research (CCR). AHRM will leverage CCR’s powerful computational resources to structure, parse and analyze de-identified electronic medical records to help better understand problems and answer questions within the health care industry.